Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.

The Pediatric infectious disease journal - 1 Dec 2016

Graf Einsiedel Hagen, Christiansen Holger, Wiegand Johannes

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzimidazoles
Share to Child, Preschool
Share to Fluorenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Identifiers

PMID: 27832030
DOI: 10.1097/INF.0000000000001336

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.PMID 27832030Read ↗

Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years.Semantic proximity Read ↗

Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age.Semantic proximity Read ↗

[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].Semantic proximity Read ↗

A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children.Semantic proximity Read ↗

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.Semantic proximity Read ↗

Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir.Semantic proximity Read ↗

Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports.Semantic proximity Read ↗

The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.Semantic proximity Read ↗

Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.Semantic proximity Read ↗

Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.Semantic proximity Read ↗

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.